to the accumulation of IDL particle and may prevent small, Role of hepatic lipase in intermediate-density lipoprotein and dense LDL formation in HD patients. small, dense low-density lipoprotein formation in hemodialysis patients.Background. It has been reported that remnant lipoproteins and small, dense low-density lipoproteins (LDLs) are risk fac-It has been well known that atherosclerotic vascular tors for cardiovascular disease. To determine whether these disease frequently occurs in uremic patients receiving risk factors are present in hemodialysis (HD) patients who long-term hemodialysis (HD) and that cardiovascular are suffering from a high incidence of atherosclerotic vascular disease, we measured concentrations of remnant lipoproteins disease is the leading cause of death in these patients and LDL particle diameter in HD patients and compared these [1, 2]. The mechanisms for developing atherosclerosis in with controls. We also measured lipoprotein lipase (LPL) and HD patients are multifactorial. However, plasma lipid hepatic triglyceride lipase (HTGL) that play important roles abnormalities have been identified as significant risk facin the generation of remnant lipoproteins and small, dense tors for cardiovascular disease in such patients. Previous LDL, and we correlated these changes with plasma lipoprotein abnormalities in HD patients.studies have revealed that an increase in plasma triglyc-Methods. Lipoproteins were separated by ultracentrifugaeride and a decrease in high-density lipoprotein (HDL) tion. Apoprotein B in very low-density lipoprotein (VLDL), cholesterol concentrations were prominent characterisand intermediate-density lipoprotein (IDL) fractions were
METHODS
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.